Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Faxeladol PR vs IR in Healthy Women
NCT03765801Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Oct 2003
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of faxeladol in neuropathic pain, chronic pain and Visceral pain (4 arms), sponsored by Grünenthal GmbH. Primary endpoints: Area Under the Curve to last measurable concentration at 23 hours, Area Under the Curve to infinity at 23 hours and 8 more. Started Oct 2003; status: completed.
02
Drugs
faxeladol
03
Conditions
neuropathic painchronic painVisceral pain
Beyond the preview
Go deeper on NCT03765801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765801.